title: [Induction therapy of transplant-eligible patients in multiple myeloma].
abstract: There have been major advances in the past decade in induction therapy for transplantation-eligible multiple myeloma (MM) patients. Induction therapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with MM. A high complete response rate has been achieved by three-drug induction regimens including novel agents both before and after ASCT without substantially increasing toxicity. A favorable response to therapy is a very important prognostic factor. This chapter reviews recent results on the most commonly used and tested doublet, triplet, quadruplet combinations for the treatment of newly diagnosed transplantation-eligible myeloma and provides guidance on choosing the optimal initial treatment regimen.
authors.forename: Jun
authors.initials: J
authors.lastname: Konishi
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Sunami
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D064592:Autografts; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy; D012307:Risk Factors; D033581:Stem Cell Transplantation